Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BNTX NASDAQ:ERAS NASDAQ:INSM NASDAQ:RVMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNTXBioNTech$89.33-3.0%$91.29$79.52▼$124.00$22.59B1.32731,653 shs886,023 shsERASErasca$19.11-1.2%$15.44$1.33▼$24.28$5.94B0.665.70 million shs3.18 million shsINSMInsmed$106.92-0.5%$105.20$90.39▼$212.75$23.18B0.782.50 million shs1.90 million shsRVMDRevolution Medicines$189.23+0.3%$168.87$34.00▼$193.82$40.23B1.372.57 million shs1.29 million shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNTXBioNTech0.00%-2.35%-0.74%-15.29%-22.05%ERASErasca0.00%-0.31%+27.83%-11.06%+1,017.54%INSMInsmed0.00%-1.29%+2.35%-20.90%+3.36%RVMDRevolution Medicines0.00%+1.65%+6.21%+39.86%+404.21%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNTXBioNTech$89.33-3.0%$91.29$79.52▼$124.00$22.59B1.32731,653 shs886,023 shsERASErasca$19.11-1.2%$15.44$1.33▼$24.28$5.94B0.665.70 million shs3.18 million shsINSMInsmed$106.92-0.5%$105.20$90.39▼$212.75$23.18B0.782.50 million shs1.90 million shsRVMDRevolution Medicines$189.23+0.3%$168.87$34.00▼$193.82$40.23B1.372.57 million shs1.29 million shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNTXBioNTech0.00%-2.35%-0.74%-15.29%-22.05%ERASErasca0.00%-0.31%+27.83%-11.06%+1,017.54%INSMInsmed0.00%-1.29%+2.35%-20.90%+3.36%RVMDRevolution Medicines0.00%+1.65%+6.21%+39.86%+404.21%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBNTXBioNTech 2.74Moderate Buy$129.1344.55% UpsideERASErasca 2.64Moderate Buy$21.6413.22% UpsideINSMInsmed 3.00Buy$209.1395.60% UpsideRVMDRevolution Medicines 2.95Moderate Buy$144.67-23.55% DownsideCurrent Analyst Ratings BreakdownLatest ERAS, RVMD, INSM, and BNTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/23/2026RVMDRevolution Medicines WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$181.00 ➝ $192.107/20/2026INSMInsmed BMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$192.007/20/2026INSMInsmed HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$220.007/20/2026ERASErasca Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$12.00 ➝ $21.007/20/2026INSMInsmed BMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy7/20/2026RVMDRevolution Medicines Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$235.00 ➝ $236.007/17/2026INSMInsmed Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/17/2026RVMDRevolution Medicines Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/15/2026INSMInsmed Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$160.00 ➝ $161.007/14/2026ERASErasca Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy7/14/2026ERASErasca Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$24.00(Data available from 7/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBNTXBioNTech$3.25B6.96$1.34 per share66.91$96.59 per share0.92ERASErascaN/AN/AN/AN/A$1.05 per shareN/AINSMInsmed$606.42M38.22N/AN/A$3.46 per share30.90RVMDRevolution Medicines$11.58M3,474.12N/AN/A$8.44 per share22.42Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBNTXBioNTech-$1.29B-$5.88N/AN/AN/A-44.39%-5.30%-4.62%8/3/2026 (Estimated)ERASErasca-$124.55M-$0.93N/AN/AN/AN/A-35.31%-29.49%8/11/2026 (Estimated)INSMInsmed-$1.28B-$5.75N/A181.22N/A-144.44%-130.11%-51.57%8/6/2026 (Estimated)RVMDRevolution Medicines-$1.13B-$7.07N/AN/AN/AN/A-83.22%-59.06%8/5/2026 (Estimated)Latest ERAS, RVMD, INSM, and BNTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2026Q2 2026ERASErasca-$0.12N/AN/AN/AN/AN/A8/6/2026Q2 2026INSMInsmed-$0.69N/AN/AN/A$393.40 millionN/A8/5/2026Q2 2026RVMDRevolution Medicines-$2.04N/AN/AN/A$1.77 millionN/A8/3/2026Q2 2026BNTXBioNTech-$2.3987N/AN/AN/A$183.75 millionN/A5/11/2026Q1 2026ERASErasca-$0.1150-$0.60-$0.4850-$0.60N/AN/A5/7/2026Q1 2026INSMInsmed-$0.90-$0.76+$0.14-$0.76$300.81 million$305.96 million5/6/2026Q1 2026RVMDRevolution Medicines-$1.83-$2.29-$0.46-$2.29$2.43 millionN/A5/4/2026Q1 2026BNTXBioNTech-$2.52-$2.2570+$0.2630-$2.43$207.42 million$136.71 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBNTXBioNTechN/AN/AN/AN/AN/AERASErascaN/AN/AN/AN/AN/AINSMInsmedN/AN/AN/AN/AN/ARVMDRevolution MedicinesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBNTXBioNTech0.018.808.74ERASErascaN/A9.529.52INSMInsmed0.804.474.10RVMDRevolution Medicines0.196.806.80Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBNTXBioNTech15.52%ERASErasca67.78%INSMInsmedN/ARVMDRevolution Medicines94.34%Insider OwnershipCompanyInsider OwnershipBNTXBioNTech19.20%ERASErasca14.20%INSMInsmed2.10%RVMDRevolution Medicines7.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBNTXBioNTech7,807252.88 million204.33 millionOptionableERASErasca120310.98 million266.83 millionOptionableINSMInsmed1,664216.75 million212.20 millionOptionableRVMDRevolution Medicines250212.60 million196.44 millionOptionableERAS, RVMD, INSM, and BNTX HeadlinesRecent News About These CompaniesGranahan Investment Management LLC Sells 56,621 Shares of Revolution Medicines, Inc. $RVMD36 minutes ago | marketbeat.comRevolution Medicines, Inc. $RVMD Shares Purchased by KBC Group NV1 hour ago | marketbeat.comABN Amro Investment Solutions Purchases Shares of 6,794 Revolution Medicines, Inc. $RVMD3 hours ago | marketbeat.comCan Revolution Medicines (RVMD) Justify Its Valuation On Daraxonrasib Survival Data?July 25 at 7:56 AM | finance.yahoo.comRevolution Medicines (RVMD) Wins FDA Review Milestone For Daraxonrasib In Pancreatic CancerJuly 25 at 7:56 AM | finance.yahoo.comKryger Capital LLC Takes $843,000 Position in Revolution Medicines, Inc. $RVMDJuly 25 at 6:16 AM | marketbeat.comRevolution Medicines, Inc. $RVMD Shares Bought by Hsbc Holdings PLCJuly 25 at 4:32 AM | marketbeat.com13,400 Shares in Revolution Medicines, Inc. $RVMD Bought by GABELLI & Co INVESTMENT ADVISERS INC.July 25 at 3:59 AM | marketbeat.com138,290 Shares in Revolution Medicines, Inc. $RVMD Acquired by PSquared Asset Management AGJuly 24 at 6:33 AM | marketbeat.comSiren L.L.C. Sells 224,095 Shares of Revolution Medicines, Inc. $RVMDJuly 24 at 6:16 AM | marketbeat.comInceptionr LLC Buys Shares of 13,143 Revolution Medicines, Inc. $RVMDJuly 24 at 6:11 AM | marketbeat.comWalleye Capital LLC Acquires New Holdings in Revolution Medicines, Inc. $RVMDJuly 24 at 5:45 AM | marketbeat.comAndra AP fonden Buys Shares of 16,600 Revolution Medicines, Inc. $RVMDJuly 24 at 3:06 AM | marketbeat.comFDA Accepts RVMD's Filing for Daraxonrasib in Pancreatic CancerJuly 23 at 2:11 PM | zacks.comSwiss National Bank Has $41.37 Million Stock Holdings in Revolution Medicines, Inc. $RVMDJuly 23 at 4:55 AM | marketbeat.comRevolution Medicines, Inc. $RVMD is Decheng Capital LLC's 9th Largest PositionJuly 23 at 4:15 AM | marketbeat.comBank of New York Mellon Corp Purchases 93,297 Shares of Revolution Medicines, Inc. $RVMDJuly 23 at 3:29 AM | marketbeat.comRevolution Medicines’ New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic CancerJuly 22, 2026 | markets.businessinsider.comRevolution Medicines' New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic CancerJuly 22, 2026 | globenewswire.comSEB Asset Management AB Acquires Shares of 69,630 Revolution Medicines, Inc. $RVMDJuly 22, 2026 | marketbeat.comRevolution Medicines, Inc. $RVMD Shares Sold by California Public Employees Retirement SystemJuly 22, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeERAS, RVMD, INSM, and BNTX Company DescriptionsBioNTech NASDAQ:BNTX$89.33 -2.73 (-2.97%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$89.50 +0.17 (+0.19%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.Erasca NASDAQ:ERAS$19.11 -0.23 (-1.19%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$19.23 +0.12 (+0.64%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.Insmed NASDAQ:INSM$106.92 -0.49 (-0.46%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$106.05 -0.87 (-0.81%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.Revolution Medicines NASDAQ:RVMD$189.23 +0.48 (+0.25%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$189.88 +0.65 (+0.34%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Freeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good Enough Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
